Shanghai Sundise Co.,Ltd. Release: Fuzheng Huayu Composition May Lead to Anti-Liver Fibrosis Treatment in U.S.

08 Nov 2011

·www.biospace.com

SAN FRANCISCO--(BUSINESS WIRE)--At the annual Liver Meeting® of American Association for Study of Liver Diseases on Nov. 6, 2011, Professor Chenghai Liu, director of the Institute of Liver Diseases Liver Diseases at Shanghai University of Traditional Chinese Medicine, revealed the botanical preparation Fuzheng Huayu (FZHY) and the newly identified compounds may help reverse liver fibrosis in hepatitis patients.

Organizations

Institute of Liver & Biliary Sciences

Shanghai University of Traditional Chinese MedicineAnhui Huayu Crafts Co., Ltd.

Indications

Liver CirrhosisLiver DiseasesHepatitis

Targets

Drugs

Hot reports

Global Drug R&D Express (Apr 2024)

PatSnap Synapse

Global Drug R&D Express (Mar 2024)

PatSnap Synapse

Global Drug R&D Express (Feb 2024)

PatSnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.